Clinical validation of droplet digital PCR assays in detecting BRAFV600-mutant circulating tumour DNA as a prognostic biomarker in patients with resected stage III melanoma receiving adjuvant therapy (COMBI-AD): a biomarker analysis from a double-blind, randomised phase 3 trial

Mahrukh M Syeda, Georgina V Long, James Garrett, Victoria Atkinson, Mario Santinami, Dirk Schadendorf, Axel Hauschild, Michael Millward, Mario Mandala, Vanna Chiarion-Sileni, Michael Smylie, Georgy M Manikhas, Reinhard Dummer, Jennifer M Wiggins, Saim Ali, Sachin Bajirao Adnaik, Monique Tan, Maya Dajee, David Polsky

Open source

DOI: 10.1016/s1470-2045(25)00139-1
Published: 2025-05
Container: The Lancet Oncology
Publisher: Elsevier BV
Open access: unknown

Credibility signals

uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

supportingDOI registered: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
supportingDOI resolves: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
supportingMetadata completeness: All 6 scored descriptive metadata groups are present. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1016/s1470-2045-25-00139-1,
  title = {Clinical validation of droplet digital PCR assays in detecting BRAFV600-mutant circulating tumour DNA as a prognostic biomarker in patients with resected stage III melanoma receiving adjuvant therapy (COMBI-AD): a biomarker analysis from a double-blind, randomised phase 3 trial},
  author = {Mahrukh M Syeda and Georgina V Long and James Garrett and Victoria Atkinson and Mario Santinami and Dirk Schadendorf and Axel Hauschild and Michael Millward and Mario Mandala and Vanna Chiarion-Sileni and Michael Smylie and Georgy M Manikhas and Reinhard Dummer and Jennifer M Wiggins and Saim Ali and Sachin Bajirao Adnaik and Monique Tan and Maya Dajee and David Polsky},
  year = {2025},
  journal = {The Lancet Oncology},
  doi = {10.1016/s1470-2045(25)00139-1},
  url = {https://doi.org/10.1016/s1470-2045(25)00139-1}
}

RIS

TY  - JOUR
TI  - Clinical validation of droplet digital PCR assays in detecting BRAFV600-mutant circulating tumour DNA as a prognostic biomarker in patients with resected stage III melanoma receiving adjuvant therapy (COMBI-AD): a biomarker analysis from a double-blind, randomised phase 3 trial
AU  - Mahrukh M Syeda
AU  - Georgina V Long
AU  - James Garrett
AU  - Victoria Atkinson
AU  - Mario Santinami
AU  - Dirk Schadendorf
AU  - Axel Hauschild
AU  - Michael Millward
AU  - Mario Mandala
AU  - Vanna Chiarion-Sileni
AU  - Michael Smylie
AU  - Georgy M Manikhas
AU  - Reinhard Dummer
AU  - Jennifer M Wiggins
AU  - Saim Ali
AU  - Sachin Bajirao Adnaik
AU  - Monique Tan
AU  - Maya Dajee
AU  - David Polsky
PY  - 2025
JO  - The Lancet Oncology
DO  - 10.1016/s1470-2045(25)00139-1
UR  - https://doi.org/10.1016/s1470-2045(25)00139-1
ER  -

APA

Syeda, M. M., Long, G. V., Garrett, J., Atkinson, V., Santinami, M., Schadendorf, D., Hauschild, A., Millward, M., Mandala, M., Chiarion-Sileni, V., Smylie, M., Manikhas, G. M., Dummer, R., Wiggins, J. M., Ali, S., Adnaik, S. B., Tan, M., Dajee, M., & Polsky, D. (2025). Clinical validation of droplet digital PCR assays in detecting BRAFV600-mutant circulating tumour DNA as a prognostic biomarker in patients with resected stage III melanoma receiving adjuvant therapy (COMBI-AD): a biomarker analysis from a double-blind, randomised phase 3 trial. The Lancet Oncology. https://doi.org/10.1016/s1470-2045(25)00139-1

Source records

crossref · retrieved 2026-09-26T00:45:44.966Z